Obsessive-Compulsive Disorder (OCD)

Categories: Genetic diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Obsessive-Compulsive Disorder

MalaCards integrated aliases for Obsessive-Compulsive Disorder:

Name: Obsessive-Compulsive Disorder 57 12 74 43 36 29 54 42 44 15 62 17 71 32
Ocd 57 74 43 6
Obsessive-Compulsive Disorder, Susceptibility to 57 6
Obsessive Compulsive Disorder 12 39
Anancastic Neurosis 12 43
Obsessive-Compulsive Neurosis 43
Obsessive Compulsive Behavior 71
Anankastic Neurosis 43



57 (Updated 05-Mar-2021)
autosomal dominant form


obsessive-compulsive disorder:
Inheritance autosomal dominant inheritance


External Ids:

Disease Ontology 12 DOID:10933
OMIM® 57 164230
KEGG 36 H01450
ICD9CM 34 300.3
MeSH 44 D009771
NCIt 50 C88411
SNOMED-CT 67 71478004
ICD10 32 F42 F42.9
MedGen 41 C0028768
UMLS 71 C0028768 C0600104

Summaries for Obsessive-Compulsive Disorder

MedlinePlus : 42 What is obsessive-compulsive disorder (OCD)? Obsessive-compulsive disorder (OCD) is a mental disorder in which you have thoughts (obsessions) and rituals (compulsions) over and over. They interfere with your life, but you cannot control or stop them. What causes obsessive-compulsive disorder (OCD)? The cause of obsessive-compulsive disorder (OCD) is unknown. Factors such as genetics, brain biology and chemistry, and your environment may play a role. Who is at risk for obsessive-compulsive disorder (OCD)? Obsessive-compulsive disorder (OCD) usually begins when you are a teen or young adult. Boys often develop OCD at a younger age than girls. Risk factors for OCD include Family history. People with a first-degree relative (such as a parent, sibling, or child) who has OCD are at higher risk. This is especially true if the relative developed OCD as a child or teen. Brain structure and functioning. Imaging studies have shown that people with OCD have differences in certain parts of the brain. Researchers need to do more studies to understand the connection between the brain differences and OCD. Childhood trauma, such as child abuse. Some studies have found a link between trauma in childhood and OCD. More research is needed to understand this relationship better. In some cases, children may develop OCD or OCD symptoms following a streptococcal infection. This is called Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS). What are the symptoms of obsessive-compulsive disorder (OCD)? People with OCD may have symptoms of obsessions, compulsions, or both: Obsessions are repeated thoughts, urges, or mental images that cause anxiety. They may involve things such as Fear of germs or contamination Fear of losing or misplacing something Worries about harm coming towards yourself or others Unwanted forbidden thoughts involving sex or religion Aggressive thoughts towards yourself or others Needing things lined up exactly or arranged in a particular, precise way Compulsions are behaviors that you feel like you need to do over and over to try to reduce your anxiety or stop the obsessive thoughts. Some common compulsions include Excessive cleaning and/or handwashing Repeatedly checking on things, such as whether the door is locked or the oven is off Compulsive counting Ordering and arranging things in a particular, precise way Some people with OCD also have a Tourette syndrome or another tic disorder. Tics are sudden twitches, movements, or sounds that people do repeatedly. People who have tics cannot stop their body from doing these things. How is obsessive-compulsive disorder (OCD) diagnosed? The first step is to talk with your health care provider about your symptoms. Your provider should do an exam and ask you about your health history. He or she needs to make sure that a physical problem is not causing your symptoms. If it seems to be a mental problem, your provider may refer you to a mental health specialist for further evaluation or treatment. Obsessive-compulsive disorder (OCD) can sometimes be hard to diagnose. Its symptoms are like those of other mental disorders, such as anxiety disorders. It is also possible to have both OCD and another mental disorder. Not everyone who has obsessions or compulsions has OCD. Your symptoms would usually be considered OCD when you Can't control your thoughts or behaviors, even when you know that they are excessive Spend at least 1 hour a day on these thoughts or behaviors Don't get pleasure when performing the behaviors. But doing them may briefly give you relief from the anxiety that your thoughts cause. Have significant problems in your daily life because of these thoughts or behaviors What are the treatments for obsessive-compulsive disorder (OCD)? The main treatments for obsessive-compulsive disorder (OCD) are cognitive behavioral therapy, medicines, or both: Cognitive behavioral therapy (CBT) is a type of psychotherapy. It teaches you different ways of thinking, behaving, and reacting to the obsessions and compulsions. One specific type of CBT that can treat OCD is called Exposure and Response Prevention (EX/RP). EX/RP involves gradually exposing you to your fears or obsessions. You learn healthy ways to deal with the anxiety they cause. Medicines for OCD include certain types of antidepressants. If those don't work for you, your provider may suggest taking some other type of psychiatric medicine. NIH: National Institute of Mental Health

MalaCards based summary : Obsessive-Compulsive Disorder, also known as ocd, is related to trichotillomania and body dysmorphic disorder, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Obsessive-Compulsive Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Serotonergic synapse and Dopaminergic synapse. The drugs Pregabalin and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and subthalamic nucleus, and related phenotypes are obsessive-compulsive behavior and depressivity

Disease Ontology : 12 An anxiety disorder that involves unwanted and repeated thoughts, feelings, ideas, sensations (obsessions), or behaviors that make them feel driven to do something (compulsions).

MedlinePlus Genetics : 43 Obsessive-compulsive disorder (OCD) is a mental health condition characterized by features called obsessions and compulsions. Obsessions are intrusive thoughts, mental images, or urges to perform specific actions. While the particular obsessions vary widely, they often include fear of illness or contamination; a desire for symmetry or getting things "just right;" or intrusive thoughts involving religion, sex, or aggression. Compulsions consist of the repetitive performance of certain actions, such as checking or verifying, washing, counting, arranging, acting out specific routines, or seeking assurance. These behaviors are performed to relieve anxiety, rather than to seek pleasure as in other compulsive behaviors like gambling, eating, or sex.While almost everyone experiences obsessive feelings and compulsive behaviors occasionally or in particular contexts, in OCD they take up more than an hour a day and cause problems with work, school, or social life. People with OCD generally experience anxiety and other distress around their need to accommodate their obsessions or compulsions.About half the time, OCD becomes evident in childhood or adolescence, and most other cases appear in early adulthood. It is unusual for OCD to start after age 40. It tends to appear earlier in males, but by adulthood it is slightly more common in females. Affected individuals can experience periods when their symptoms increase or decrease in severity, but the condition usually does not go away completely.Some people with OCD have additional mental health disorders such as generalized anxiety, depression, phobias, panic disorders, or schizophrenia. OCD can also occur in people with other neurological conditions such as Tourette syndrome and similar disorders, traumatic brain injury, stroke, or dementia.

OMIM® : 57 Obsessive-compulsive disorder (OCD) is characterized by recurring obsessions and/or compulsions and has been estimated to affect nearly 5 million people in the United States (Karno et al., 1988). Evidence for a strong genetic component in OCD comes from twin studies, family genetics studies, and segregation analyses, as reviewed by Alsobrook et al. (2002). Zhang et al. (2002) suggested that hoarding is likely to be an evolutionarily conserved trait that, in times of adversity, was associated with increased survival and reproductive fitness. However, extreme forms of this trait are associated with marked disability and poor response to treatment (Black et al., 1998; Mataix-Cols et al., 1999). (164230) (Updated 05-Mar-2021)

KEGG : 36 Obsessive-compulsive disorder (OCD) is a psychiatric disorder characterized by recurrent, intrusive and disturbing thoughts as well as by repetitive stereotypic behaviors. OCD is a complex disorder and its pathogenesis is most likely influenced by both genetic and environmental factors. Although more than 140 candidate gene studies have been conducted, the findings have been inconclusive due to small sample size and few study replications. Many studies suggest that abnormal serotonergic neurotransmission is one of the most consistent biological findings in OCD. Studies have also reported dopaminergic abnormalities in the basal ganglia and nucleus accumbens, as well as altered glutamate transmission. First line treatments for this disorder are cognitive behavioral therapy (exposure and response prevention) and selective serotonin reuptake inhibitors (SSRIs). In recent years, one of the promising novel treatment strategies developed to improve the efficacy of treatment for patients with OCD is acceptance and commitment therapy (ACT). Recent studies have suggested that age of onset is an important factor in subtyping OCD. Early-onset OCD has been proposed to be associated with greater symptom severity, a higher prevalence of tic-related disorders, a more familial form of the condition, and a greater prevalence of psychiatry disorders in first-degree relatives as compared to late-onset OCD.

PubMed Health : 62 About obsessive-compulsive disorder: We all know the worrying feeling that we have forgotten to do something, like turning off the oven or locking the door. And it might be a good idea to double-check if you aren't absolutely sure. But some people are so worried about forgetting to do something that they feel the urge to check over and over again. Compulsive urges like this may gradually come to dominate their whole life. There are different types of obsessive-compulsive disorder (OCD). Some people are so afraid of germs that they constantly wash their hands. Others can't stop counting things, cleaning their surroundings or obsessing over the same repetitive thoughts. Regardless of the kind of ritual they may have developed, people who have OCD just can't stop doing these things.

Wikipedia : 74 Obsessive-compulsive disorder (OCD) is a mental disorder in which a person has certain thoughts... more...

Related Diseases for Obsessive-Compulsive Disorder

Diseases related to Obsessive-Compulsive Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 423)
# Related Disease Score Top Affiliating Genes
1 trichotillomania 33.0 SLITRK1 SLC1A1 MAOA DRD4
2 body dysmorphic disorder 32.9 SLC6A4 SLC1A1 OXT MAOA HTR2A
3 gilles de la tourette syndrome 32.8 SLITRK1 SLC6A4 SLC6A3 SGCE MAOA HTR3A
4 neurotic disorder 32.7 SLC6A4 OXT MAOA HTR2A HTR1A COMT
5 autism spectrum disorder 32.6 TPH2 SLC6A4 SLC6A3 SLC1A1 OXT MAOA
6 fibromyalgia 32.6 SLC6A4 HTR3A HTR2A COMT BDNF
7 tic disorder 32.5 TPH2 SLITRK1 SLC6A4 SLC6A3 SLC1A1 MAOA
8 schizophrenia 32.5 TPH2 TPH1 SLC6A4 SLC6A3 SLC1A1 OXT
9 anxiety 32.4 TPH2 TPH1 SLC6A4 SLC6A3 SLC1A1 OXT
10 depression 32.4 TPH2 TPH1 SLC6A4 MAOA HTR3A HTR2A
11 eating disorder 32.4 SLC6A4 SLC6A3 DRD2 COMT BDNF
12 obsessive-compulsive personality disorder 32.2 SLC6A4 HTR2A COMT
13 personality disorder 32.2 TPH2 TPH1 SLC6A4 SLC6A3 MAOA HTR3A
14 generalized anxiety disorder 32.2 TPH1 SLC6A4 SLC6A3 MAOA HTR3A HTR2A
15 mental depression 32.2 TPH2 TPH1 SLC6A4 SLC6A3 OXT MAOA
16 panic disorder 32.2 TPH2 TPH1 SLC6A4 SLC6A3 MAOA HTR3A
17 post-traumatic stress disorder 32.2 SLC6A4 MAOA HTR2A DRD2 COMT BDNF
18 anorexia nervosa 32.1 SLC6A4 OXT MAOA HTR2A HTR1A DRD4
19 social phobia 32.1 SLC6A4 OXT MAOA HTR3A HTR2A HTR1A
20 agoraphobia 32.1 SLC6A4 MAOA HTR2A HTR1A COMT BDNF
21 major depressive disorder 32.1 TPH2 TPH1 SLC6A4 SLC6A3 OXT MAOA
22 bipolar disorder 32.1 TPH2 TPH1 SLC6A4 SLC6A3 MAOA HTR3A
23 acute stress disorder 32.0 SLC6A4 OXT HTR1A BDNF
24 hypochondriasis 31.9 SLC6A4 SLC1A1 OXT HTR2A HTR1A BDNF
25 mood disorder 31.9 TPH2 TPH1 SLC6A4 SLC6A3 MAOA HTR3A
26 movement disease 31.9 SLC6A3 SGCE DRD2 BDNF
27 bulimia nervosa 31.8 SLC6A4 OXT MAOA HTR3A HTR2A HTR1B
28 alexithymia 31.8 SLC6A4 OXT HTR1A DRD2 COMT
29 autism 31.8 TPH2 TPH1 SLC6A4 SLC6A3 SLC1A1 OXT
30 choreatic disease 31.8 SLC6A3 SGCE DRD2 BDNF
31 chronic tic disorder 31.8 SLITRK1 DRD4
32 separation anxiety disorder 31.8 SLC6A4 SLC6A3 OXT MAOA HTR1A DRD4
33 pathological gambling 31.8 TPH1 SLC6A4 SLC6A3 MAOA HTR2A HTR1A
34 schizoaffective disorder 31.7 SLC6A4 SLC1A1 HTR2A HTR1A DRD2 COMT
35 dysthymic disorder 31.7 SLC6A4 SLC6A3 MAOA HTR2A HTR1A DRD4
36 kleptomania 31.7 SLC6A4 MAOA HTR1A DRD2 COMT
37 somatization disorder 31.7 SLC6A4 OXT HTR1A COMT
38 sexual disorder 31.7 SLC6A4 OXT HTR2A HTR1A BDNF
39 substance abuse 31.6 SLC6A4 SLC6A3 MAOA HTR2A HTR1B HTR1A
40 phobia, specific 31.6 SLC6A4 OXT MAOA HTR2A HTR1A COMT
41 dystonia 31.6 TPH1 SLC6A3 SGCE HTR2A DRD2 COMT
42 psychotic disorder 31.6 TPH2 TPH1 SLC6A4 SLC6A3 SLC1A1 OXT
43 traumatic brain injury 31.6 DRD2 COMT BDNF
44 brain injury 31.6 DRD2 COMT BDNF
45 alcohol use disorder 31.5 SLC6A4 SLC6A3 HTR3A HTR2A HTR1B HTR1A
46 oppositional defiant disorder 31.5 TPH2 SLC6A4 SLC6A3 OXT MAOA HTR2A
47 pervasive developmental disorder 31.5 SLC6A4 OXT HTR2A DRD2 BDNF
48 essential tremor 31.5 SLC6A3 COMT BDNF
49 intermittent explosive disorder 31.5 SLC6A4 OXT MAOA HTR2A HTR1A COMT
50 bipolar i disorder 31.4 TPH2 SLC6A4 HTR2A HTR1A DRD2 COMT

Comorbidity relations with Obsessive-Compulsive Disorder via Phenotypic Disease Network (PDN):

Anxiety Dependent Personality Disorder
Dysthymic Disorder Generalized Anxiety Disorder
Hypothyroidism Major Depressive Disorder
Obsessive-Compulsive Personality Disorder Schizophreniform Disorder

Graphical network of the top 20 diseases related to Obsessive-Compulsive Disorder:

Diseases related to Obsessive-Compulsive Disorder

Symptoms & Phenotypes for Obsessive-Compulsive Disorder

Human phenotypes related to Obsessive-Compulsive Disorder:

# Description HPO Frequency HPO Source Accession
1 obsessive-compulsive behavior 31 very rare (1%) HP:0000722
2 depressivity 31 HP:0000716
3 anxiety 31 HP:0000739
4 collectionism 31 HP:0030212
5 skin-picking 31 HP:0012166

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
obsessive-compulsive disorder

Clinical features from OMIM®:

164230 (Updated 05-Mar-2021)

UMLS symptoms related to Obsessive-Compulsive Disorder:

photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances, mental and behavioral signs and symptoms, psychiatric symptom

GenomeRNAi Phenotypes related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.88 CDK20
2 Decreased viability GR00055-A-2 9.88 CDK20
3 Decreased viability GR00106-A-0 9.88 MAOA
4 Decreased viability GR00221-A-4 9.88 CDK20
5 Decreased viability GR00240-S-1 9.88 COMT
6 Decreased viability GR00249-S 9.88 SLC6A4 COMT HIVEP1 SGCE TPH1
7 Decreased viability GR00342-S-1 9.88 CDK20
8 Decreased viability GR00342-S-2 9.88 CDK20
9 Decreased viability GR00342-S-3 9.88 CDK20
10 Decreased viability GR00381-A-1 9.88 HTR1A HTR3A SLC6A4 IQCK
11 Decreased viability GR00381-A-3 9.88 HTR1A HTR3A SLC6A4
12 Decreased viability GR00386-A-1 9.88 COMT HIVEP1 TPH2
13 Decreased viability GR00402-S-2 9.88 HTR1A HTR3A IQCK TPH2

MGI Mouse Phenotypes related to Obsessive-Compulsive Disorder:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 BDNF COMT DRD2 DRD4 HTR1A HTR1B
2 growth/size/body region MP:0005378 10.17 BDNF CDK20 DRD2 HIVEP1 HTR1B HTR3A
3 cardiovascular system MP:0005385 10.14 COMT DRD2 HIVEP1 HTR1A HTR1B MAOA
4 homeostasis/metabolism MP:0005376 10.13 BDNF COMT DRD2 DRD4 HTR1A HTR3A
5 endocrine/exocrine gland MP:0005379 10.11 BDNF COMT DRD2 HTR1B HTR2A HTR3A
6 adipose tissue MP:0005375 10 DRD2 HTR1A HTR1B OXT SLC1A1 TPH1
7 nervous system MP:0003631 9.83 BDNF CDK20 COMT DRD2 DRD4 HTR1A
8 muscle MP:0005369 9.76 DRD2 HTR1B HTR2A HTR3A SGCE SLC6A3
9 taste/olfaction MP:0005394 8.92 BDNF DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Obsessive-Compulsive Disorder

PubMed Health treatment related to Obsessive-Compulsive Disorder: 62

Although there's no “cure” for OCD, with good professional help the symptoms can be reduced to a tolerable level, enabling people with OCD to start leading normal lives again. People with OCD are usually advised to have psychological treatment . Cognitive behavioral therapy (CBT) in particular has been proven to be an effective treatment for OCD. In Germany, it is offered by behavioral therapists (in German: Verhaltenstherapeuten ). Medication for depression (antidepressants) may be considered in addition to CBT, or if psychological treatment isn't an option (yet). Selective serotonin re-uptake inhibitors (SSRIs) are commonly used for this purpose. Apart from these treatments , self-help is an option, for example by talking to other people with OCD in a support group. Some people like to use books or websites to learn about their obsessive-compulsive behaviors and deal with them. Others may try to manage their OCD using relaxation techniques like meditation or autogenic training.

Drugs for Obsessive-Compulsive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 201)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
Ethanol Approved Phase 4 64-17-5 702
Cycloserine Approved Phase 4 68-41-7 401 6234
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585 135398745
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Topiramate Approved Phase 4 97240-79-4 5284627
Haloperidol Approved Phase 4 52-86-8 3559
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Ondansetron Approved Phase 4 99614-02-5 4595
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
Citalopram Approved Phase 4 59729-33-8 2771
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
Propranolol Approved, Investigational Phase 4 525-66-6 4946
Sertraline Approved Phase 4 79617-96-2 68617
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
Maleic acid Experimental Phase 4 110-16-7 444266
21 Quetiapine Fumarate Phase 4 111974-72-2
22 Antidepressive Agents, Tricyclic Phase 4
23 Anticonvulsants Phase 4
24 Hormones Phase 4
25 calcium channel blockers Phase 4
26 Antibiotics, Antitubercular Phase 4
27 Anti-Infective Agents Phase 4
28 Antitubercular Agents Phase 4
29 Anti-Bacterial Agents Phase 4
30 Respiratory System Agents Phase 4
31 Antioxidants Phase 4
32 N-monoacetylcystine Phase 4
33 Expectorants Phase 4
34 Pharmaceutical Solutions Phase 4
35 Central Nervous System Stimulants Phase 4
36 Dopamine Uptake Inhibitors Phase 4
37 Duloxetine Hydrochloride Phase 4
38 Hypoglycemic Agents Phase 4
39 Haloperidol decanoate Phase 4
40 Antipsychotic Agents Phase 4
41 Calcium, Dietary Phase 4
42 Antiparkinson Agents Phase 4
43 Gastrointestinal Agents Phase 4
44 Dermatologic Agents Phase 4
45 Antiemetics Phase 4
46 Antirheumatic Agents Phase 4
47 Anti-Inflammatory Agents Phase 4
48 Analgesics, Non-Narcotic Phase 4
49 Anti-Inflammatory Agents, Non-Steroidal Phase 4
50 Cyclooxygenase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 412)
# Name Status NCT ID Phase Drugs
1 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
2 Treatment With Escitalopram (Cipralex®) for Adolescents With Obsessive-Compulsive Disorder: Efficacy, Safety, and Changes in Executive Functions, Metacognition, and Regional Brain Activations. Unknown status NCT00708240 Phase 4 Escitalopram
3 Cost-Effectiveness of Adding Web-Based CBT to Luvox CR for OCD Unknown status NCT00743834 Phase 4 Luvox CR
4 Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial. Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
5 Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study Completed NCT00466609 Phase 4 Clomipramine (fluoxetine plus clomipramine);Quetiapine (fluoxetine plus quetiapine);Placebo (fluoxetine plus placebo)
6 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Completed NCT00994786 Phase 4 pregabalin;Placebo
7 An Long Term Trial on Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
8 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Completed NCT01339858 Phase 4 N-Acetyl Cysteine
9 Efficacy of Exposure and Response Prevention(ERP) and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder Completed NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
10 Escitalopram for the Treatment of Obsessive Compulsive Disorder Completed NCT00116532 Phase 4 Escitalopram
11 Neurobiology/Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
12 Reclaim® Deep Brain Stimulation Therapy for Obsessive-Compulsive Disorder: Post-Market Clinical Follow-up Study (OCD PMCF) Completed NCT01135745 Phase 4
13 Duloxetine for the Treatment of Obsessive Compulsive Disorder Completed NCT00464698 Phase 4 Duloxetine
14 Escitalopram in the Treatment of Patient Suffering From Scizophrenia and Obsessive Compulsive Disorder- an Open Label Study Completed NCT00456937 Phase 4 Escitalopram
15 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Completed NCT00211744 Phase 4 topiramate
16 Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? A Randomized, Double-blind, Placebo-controlled National Study Completed NCT02656342 Phase 4 D-Cycloserine;Placebo
17 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Randomized Open Trial for Any Patient. Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
18 SSRI-Induced Activation Syndrome in Pediatric Obsessive Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
19 A Study of Topiramate Augmentation in Serotonin Reuptake Inhibitor (SRI) -Refractory Obsessive Compulsive Disorder Completed NCT00182520 Phase 4 Topiramate;placebo
20 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder (Randomized, Double-blind, Multi-center Study) Completed NCT00723060 Phase 4 escitalopram
21 Internet-based Cognitive Behavior Therapy in Combination With D-Cycloserine for Obsessive Compulsive Disorder: A Double Blinded Randomized Controlled Trial Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
22 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
23 Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study Completed NCT00796497 Phase 4 ondansetron
24 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
25 12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
26 A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
27 Clinical, Neurocognitive and Neuroimaging Variables Associated With Response to Treatment in Patients With OCD Recruiting NCT03993535 Phase 4 selective serotonin reuptake inhibitor
28 A 12-week Randomized Controlled Trial of Probiotic Treatment (Lactobacillus Helveticus R0052 and Bifidobacterium Longum R0175) vs Placebo in Adult Obsessive Compulsive Disorder Recruiting NCT02334644 Phase 4
29 The Role of Serotonin in Compulsive Behavior in Humans: Underlying Brain Mechanisms Recruiting NCT04336228 Phase 4 Escitalopram;Placebo oral tablet
30 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
31 Double-Blind, Randomized, Placebo-Controlled Trial of Naproxen Sodium for the Treatment of Obsessive Compulsive Symptoms in Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infections (PANDAS) Recruiting NCT04015596 Phase 4 Naproxen Sodium
32 Fear Conditioning, Extinction and Recall in Healthy Subjects and in Obsessive-compulsive Disorder Patients Pre and Post Treatment With Sertraline. Active, not recruiting NCT03068429 Phase 4 Sertraline Hydrochloride
33 Controlled Trial of Deep Brain Stimulation for Obsessive-Compulsive Disorder Active, not recruiting NCT00640133 Phase 4
34 Brief Intervention for OCD Fears Suspended NCT02790710 Phase 4 Propanolol;Placebo
35 A Pilot Treatment Study of Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder Terminated NCT00592852 Phase 4 fluoxetine
36 SME3110 (Fluvoxamine Maleate) in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-blind, Randomized, Placebo-controlled Study Terminated NCT00352768 Phase 4 Fluvoxamine maleate;Placebo
37 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
38 Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder: A Pilot Study Unknown status NCT02590445 Phase 2, Phase 3
39 Safety and Effectiveness of Capsulotomy in Refractory Obsessive-Compulsive Disorder Unknown status NCT02375152 Phase 2, Phase 3
40 Pharmacogenetics in Primary Care Psychotropics Unknown status NCT03232502 Phase 3
41 2/3 Treatment of Anxiety in Autism Spectrum Disorder Completed NCT02028247 Phase 3
42 A Controlled Trial of Daily Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder Completed NCT00369642 Phase 3
43 Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study Completed NCT00254735 Phase 3 quetiapine fumarate;SSRI/Clomipramine
44 Treatment of Severe and Resistant Obsessive-compulsive Disorder by High-frequency Stimulation of the Ventral Striatum and the Subthalamic Nucleus Completed NCT01329133 Phase 3
45 A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder Completed NCT01933919 Phase 3 Fluvoxamine maleate;Placebo
46 Phase III Open Study of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder in Adults Completed NCT00305500 Phase 3 escitalopram
47 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder Completed NCT00187928 Phase 3 Topiramate
48 Comparison of the Efficacy of Subthalamic Nucleus, Caudate Nucleus and Nucleus Accumbens Electric Stimulation in Severe and Resistant Obsessive-compulsive Disorder. Completed NCT01807403 Phase 3
49 Treatment of Pediatric Obsessive-Compulsive Disorder Completed NCT00000384 Phase 3 Sertraline
50 Differential Efficacy of Memantine for Obsessive-compulsive Disorder vs. Generalized Anxiety Disorder: an Open-label Trial Completed NCT00674219 Phase 3 Memantine

Search NIH Clinical Center for Obsessive-Compulsive Disorder

Inferred drug relations via UMLS 71 / NDF-RT 51 :

Citalopram hydrobromide
Clomipramine Hydrochloride
Fluoxetine Hydrochloride
Fluvoxamine Maleate
Paroxetine Hydrochloride
Sertraline Hydrochloride
Venlafaxine hydrochloride

Cochrane evidence based reviews: obsessive-compulsive disorder

Genetic Tests for Obsessive-Compulsive Disorder

Genetic tests related to Obsessive-Compulsive Disorder:

# Genetic test Affiliating Genes
1 Obsessive-Compulsive Disorder 29 HTR2A SLC6A4

Anatomical Context for Obsessive-Compulsive Disorder

MalaCards organs/tissues related to Obsessive-Compulsive Disorder:

Brain, Cortex, Subthalamic Nucleus, Skin, Prefrontal Cortex, Amygdala, Eye

Publications for Obsessive-Compulsive Disorder

Articles related to Obsessive-Compulsive Disorder:

(show top 50) (show all 12979)
# Title Authors PMID Year
5-HT2A promoter polymorphism -1438G/A in children and adolescents with obsessive-compulsive disorders. 61 54 6 57
12476319 2002
Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. 6 57
14593431 2003
Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. 57 61 54
16642437 2006
Association between the COMT locus and obsessive-compulsive disorder in females but not males. 54 61 57
11840516 2002
Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder. 57 54 61
10331110 1999
5-HT2A promoter polymorphism -1438G/A, anorexia nervosa, and obsessive-compulsive disorder. 6 61 54
9635956 1998
Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. 57 54 61
9114031 1997
Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder. Comparison with Tourette's syndrome and healthy controls. 61 57 54
7524462 1994
Genomewide linkage analysis in Costa Rican families implicates chromosome 15q14 as a candidate region for OCD. 61 57
21691774 2011
Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. 61 57
20418887 2010
Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. 57 61
17713528 2007
Familial and sporadic subtypes of early-onset Obsessive-Compulsive disorder. 57 61
15820710 2005
Replication study supports evidence for linkage to 9p24 in obsessive-compulsive disorder. 57 61
15272418 2004
Genome-wide linkage analysis of families with obsessive-compulsive disorder ascertained through pediatric probands. 61 57
12116192 2002
Genomewide scan of hoarding in sib pairs in which both sibs have Gilles de la Tourette syndrome. 61 57
11840360 2002
Complex segregation analysis provides compelling evidence for a major gene underlying obsessive-compulsive disorder and for heterogeneity by sex. 61 57
11058433 2000
Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. 57 61
10484953 1999
Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. 61 57
9721822 1998
The epidemiology of obsessive-compulsive disorder in five US communities. 61 57
3264144 1988
Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder. 42 61
33384007 2021
International consensus on a standard set of outcome measures for child and youth anxiety, depression, obsessive-compulsive disorder, and post-traumatic stress disorder. 61 42
33341172 2021
Impact of Bipolar Disorder and Obsessive-Compulsive Disorder Comorbidity on Neurocognitive Profile: A Mini-Review. 61 42
33370731 2020
The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. 6
15364038 2004
A human serotonin transporter mutation causes constitutive activation of transport activity. 6
12869649 2003
Serum levels of brain-derived neurotrophic factor in drug-naïve obsessive-compulsive patients: a case-control study. 61 54
19664825 2010
Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. 61 54
19676096 2010
Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: a [11C]DASB PET study. 61 54
19660554 2010
The role of the brain-derived neurotrophic factor (BDNF) val66met variant in the phenotypic expression of obsessive-compulsive disorder (OCD). 61 54
19219856 2009
Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers. 61 54
19717141 2009
The drug-naïve OCD patients imaging genetics, cognitive and treatment response study: methods and sample description. 54 61
20098825 2009
In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. 61 54
19523495 2009
Dopamine D1 receptor binding in the striatum of patients with obsessive-compulsive disorder. 54 61
18706700 2009
Functional coding variation in recombinant inbred mouse lines reveals multiple serotonin transporter-associated phenotypes. 61 54
19179283 2009
Enhanced activity of human serotonin transporter variants associated with autism. 54 61
18957375 2009
Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. 54 61
18354388 2008
Catechol-O-methyltransferase (COMT): a gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. 61 54
17805313 2008
Decision-making impairment is related to serotonin transporter promoter polymorphism in a sample of patients with obsessive-compulsive disorder. 61 54
18603313 2008
Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: systematic review. 54 61
18186076 2008
The role of 5-HT2A and 5-HT2C receptors in the signal attenuation rat model of obsessive-compulsive disorder. 61 54
18339223 2008
Polymorphism C in the serotonin transporter gene (SLC6A4) in questionable dementia and Alzheimer's disease. 61 54
18490109 2008
Association between a common haplotype in the COMT gene region and psychiatric disorders in individuals with 22q11.2DS. 54 61
17949513 2008
A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder. 61 54
18055562 2008
Extensive genotyping of the BDNF and NTRK2 genes define protective haplotypes against obsessive-compulsive disorder. 61 54
17884018 2008
SERT Ileu425Val in autism, Asperger syndrome and obsessive-compulsive disorder. 61 54
18197083 2008
Design of electrochemical biosensor systems for the detection of specific DNA sequences in PCR-amplified nucleic acids related to the catechol-O-methyltransferase Val108/158Met polymorphism based on intrinsic guanine signal. 61 54
18181582 2008
The role of oxytocin in neuropsychiatric disorders. 61 54
18336283 2008
A large case-control study of common functional SLC6A4 and BDNF variants in obsessive-compulsive disorder. 54 61
17375136 2007
Serotonin transporter phosphorylation by cGMP-dependent protein kinase is altered by a mutation associated with obsessive compulsive disorder. 61 54
17913921 2007
The met(158) allele of catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: case-control study and meta-analysis. 61 54
17264842 2007
Reduced midbrain-pons serotonin transporter binding in patients with obsessive-compulsive disorder. 54 61
17430417 2007

Variations for Obsessive-Compulsive Disorder

ClinVar genetic disease variations for Obsessive-Compulsive Disorder:

# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CDK20 NM_001039803.2(CDK20):c.564G>A (p.Trp188Ter) SNV Pathogenic 375376 rs1057519438 9:90584834-90584834 9:87969919-87969919
2 HIVEP1 NM_002114.4(HIVEP1):c.4089G>C (p.Met1363Ile) SNV Pathogenic 375377 rs776300630 6:12124117-12124117 6:12123884-12123884
3 HTR2A HTR2A, -1438G-A SNV risk factor 12937
4 SLC6A4 NM_001045.6(SLC6A4):c.1273A>G (p.Ile425Val) SNV risk factor 12935 rs28914832 17:28538374-28538374 17:30211356-30211356

Copy number variations for Obsessive-Compulsive Disorder from CNVD:

# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 77765 13 47471310 47471410 Deletion Obsessive-compulsive disorder
2 160222 22 11800000 24300000 Deletion Obsessive-compulsive disorder

Expression for Obsessive-Compulsive Disorder

Search GEO for disease gene expression data for Obsessive-Compulsive Disorder.

Pathways for Obsessive-Compulsive Disorder

Pathways related to Obsessive-Compulsive Disorder according to KEGG:

# Name Kegg Source Accession
1 Serotonergic synapse hsa04726
2 Dopaminergic synapse hsa04728
3 Glutamatergic synapse hsa04724

Pathways related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
11.69 TPH2 TPH1 MAOA
Show member pathways
11.64 TPH2 TPH1 MAOA
Show member pathways
Show member pathways
Show member pathways
Show member pathways
16 10.7 MAOA COMT
Show member pathways

GO Terms for Obsessive-Compulsive Disorder

Cellular components related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.32 SLITRK1 SLC6A4 SLC6A3 SLC1A1 SGCE MAOA
2 plasma membrane GO:0005886 10.3 SLITRK1 SLC6A4 SLC6A3 SLC1A1 SGCE HTR3A
3 integral component of plasma membrane GO:0005887 10.02 SLC6A4 SLC6A3 SLC1A1 SGCE HTR3A HTR2A
4 synapse GO:0045202 9.98 SLITRK1 SLC6A4 SLC1A1 HTR3A HTR2A HTR1A
5 glutamatergic synapse GO:0098978 9.88 SLITRK1 HTR3A HTR2A DRD4 DRD2
6 neuron projection GO:0043005 9.85 TPH2 TPH1 SLC6A4 SLC6A3 SLC1A1 HTR3A
7 axon GO:0030424 9.8 SLC6A3 SLC1A1 HTR3A HTR2A DRD2 COMT
8 dendrite GO:0030425 9.61 SLC1A1 SGCE HTR2A HTR1B HTR1A DRD4
9 integral component of postsynaptic membrane GO:0099055 9.55 SLC6A4 SLC6A3 HTR3A HTR2A DRD2
10 dopaminergic synapse GO:0098691 9.49 SLC6A3 DRD2
11 G protein-coupled serotonin receptor complex GO:0098666 9.46 HTR2A HTR1B
12 serotonergic synapse GO:0099154 9.4 SLC6A4 HTR1B
13 integral component of presynaptic membrane GO:0099056 9.1 SLC6A4 SLC6A3 HTR3A HTR2A HTR1B DRD2

Biological processes related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.31 OXT HTR3A HTR2A HTR1B HTR1A DRD4
2 response to drug GO:0042493 9.93 SLC6A4 SLC6A3 SLC1A1 HTR2A DRD2 COMT
3 cellular calcium ion homeostasis GO:0006874 9.88 HTR2A DRD4 DRD2
4 response to ethanol GO:0045471 9.88 SLC6A3 HTR3A HTR1B DRD2
5 circadian rhythm GO:0007623 9.86 TPH2 TPH1 SLC6A4
6 memory GO:0007613 9.85 SLC6A4 OXT HTR2A BDNF
7 synapse assembly GO:0007416 9.83 SLITRK1 DRD2 BDNF
8 positive regulation of synapse assembly GO:0051965 9.82 SLITRK1 OXT BDNF
9 social behavior GO:0035176 9.81 SLC6A4 OXT DRD4
10 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.8 HTR2A HTR1B HTR1A DRD4
11 chemical synaptic transmission GO:0007268 9.8 SLC1A1 HTR3A HTR2A HTR1B HTR1A DRD4
12 regulation of synaptic vesicle exocytosis GO:2000300 9.79 HTR2A HTR1B DRD2
13 regulation of heart rate GO:0002027 9.77 SLC1A1 OXT DRD2
14 response to amphetamine GO:0001975 9.75 OXT DRD4 DRD2
15 behavioral fear response GO:0001662 9.74 SLC1A1 HTR1A DRD4
16 regulation of dopamine secretion GO:0014059 9.73 HTR2A HTR1B DRD2
17 bone remodeling GO:0046849 9.71 TPH1 HTR1B
18 response to iron ion GO:0010039 9.71 SLC6A3 DRD2
19 vasoconstriction GO:0042310 9.71 SLC6A4 HTR1B HTR1A
20 neurotransmitter biosynthetic process GO:0042136 9.7 SLC6A4 SLC6A3
21 positive regulation of renal sodium excretion GO:0035815 9.7 OXT DRD2
22 catecholamine metabolic process GO:0006584 9.7 MAOA COMT
23 G protein-coupled receptor internalization GO:0002031 9.7 HTR1B DRD2
24 dopamine metabolic process GO:0042417 9.7 DRD4 DRD2 COMT
25 grooming behavior GO:0007625 9.69 OXT DRD2
26 prepulse inhibition GO:0060134 9.69 SLC6A3 DRD2
27 synaptic transmission, dopaminergic GO:0001963 9.69 DRD4 DRD2
28 behavior GO:0007610 9.69 HTR2A HTR1B HTR1A
29 neurotransmitter catabolic process GO:0042135 9.68 MAOA COMT
30 sleep GO:0030431 9.68 OXT HTR2A
31 negative regulation of voltage-gated calcium channel activity GO:1901386 9.68 DRD4 DRD2
32 regulation of behavior GO:0050795 9.67 HTR1B HTR1A
33 monoamine transport GO:0015844 9.67 SLC6A4 SLC6A3
34 aromatic amino acid family metabolic process GO:0009072 9.67 TPH2 TPH1
35 behavioral response to ethanol GO:0048149 9.66 DRD4 DRD2
36 adenohypophysis development GO:0021984 9.66 SLC6A3 DRD2
37 hyaloid vascular plexus regression GO:1990384 9.65 SLC6A3 DRD2
38 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.65 HTR1B HTR1A
39 behavioral response to cocaine GO:0048148 9.65 HTR2A DRD4 DRD2
40 indolalkylamine biosynthetic process GO:0046219 9.63 TPH2 TPH1
41 sperm ejaculation GO:0042713 9.63 SLC6A4 OXT
42 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.62 DRD4 DRD2
43 response to histamine GO:0034776 9.61 DRD4 DRD2
44 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.61 DRD4 DRD2
45 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.61 HTR2A HTR1B DRD2
46 serotonin biosynthetic process GO:0042427 9.6 TPH2 TPH1
47 dopamine catabolic process GO:0042420 9.58 SLC6A3 MAOA COMT
48 regulation of dopamine metabolic process GO:0042053 9.54 SLC6A3 HTR1A DRD4
49 drinking behavior GO:0042756 9.43 OXT HTR1B DRD2
50 serotonin receptor signaling pathway GO:0007210 9.33 HTR3A HTR2A HTR1A

Molecular functions related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 symporter activity GO:0015293 9.67 SLC6A4 SLC6A3 SLC1A1
2 neurotransmitter transporter activity GO:0005326 9.48 SLC6A4 SLC6A3
3 monoamine transmembrane transporter activity GO:0008504 9.46 SLC6A4 SLC6A3
4 G protein-coupled serotonin receptor activity GO:0004993 9.46 HTR2A HTR1B HTR1A DRD4
5 dopamine neurotransmitter receptor activity GO:0004952 9.43 DRD4 DRD2
6 dopamine binding GO:0035240 9.43 SLC6A3 DRD4 DRD2
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.4 TPH2 TPH1
8 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.37 DRD4 DRD2
9 neurotransmitter receptor activity GO:0030594 9.35 HTR3A HTR2A HTR1B HTR1A DRD4
10 tryptophan 5-monooxygenase activity GO:0004510 9.32 TPH2 TPH1
11 serotonin binding GO:0051378 9.02 SLC6A4 HTR3A HTR2A HTR1B HTR1A

Sources for Obsessive-Compulsive Disorder

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....